Ozempic & PAD: Benefits for All Diabetes Types
- Semaglutide improves walking distance in patients with diabetes and early symptomatic peripheral arterial disease (PAD),according to a new analysis.
- The original STRIDE trial, which involved 792 patients with diabetes and PAD, randomly assigned participants to either semaglutide 1 mg or a placebo.
- The primary endpoint showed that semaglutide substantially improved maximum walking distance after 52 weeks.
Discover how semaglutide, a primary_keyword, offers significant benefits for diabetes patients battling peripheral arterial disease (PAD).This groundbreaking analysis reveals that the GLP-1 receptor agonist improves walking distance, a crucial indicator for those with heart complications and a secondary_keyword. notably, these positive effects hold true irrespective of factors such as diabetes duration, body mass index, or insulin use. News Directory 3 brings you the latest on this vital study showing that this medication could reshape the treatment landscape for people with diabetes. Curious about the mechanisms behind these results? Discover what’s next …
Semaglutide Eases PAD Symptoms in Diabetes Patients
Updated June 22,2025
Semaglutide improves walking distance in patients with diabetes and early symptomatic peripheral arterial disease (PAD),according to a new analysis. The benefits of this secondary_keyword_2, which is often an initial sign of cardiovascular issues in diabetics, appear consistent regardless of diabetes duration, body mass index, HbA1c levels, or use of SGLT2 inhibitors or insulin.
The original STRIDE trial, which involved 792 patients with diabetes and PAD, randomly assigned participants to either semaglutide 1 mg or a placebo. All patients experienced intermittent claudication and had an ankle-brachial index of 0.9 or less, or a toe-brachial index of 0.7 or less.
The primary endpoint showed that semaglutide substantially improved maximum walking distance after 52 weeks. For the new subanalysis, researchers assessed semaglutide’s treatment effect versus placebo, considering baseline diabetes characteristics such as HbA1C, diabetes duration, and diabetes intensity.
The study found that the median diabetes duration among participants was 12.2 years,the average baseline HbA1c was 7.1%, and the baseline BMI was 28.7 kg/m2. Approximately two-thirds of the patients were taking an SGLT2 inhibitor, and about 32% were using insulin.
Improvements in maximum walking distance with semaglutide were comparable, regardless of:
- Diabetes duration (ETR, 1.15 for less than 10 years vs. 1.13 for 10 years or more).
- BMI (ETR, 1.12 for less than 30 kg/m2 vs. 1.16 for 30 kg/m2 or more).
- HbA1c (ETR, 1.13 for less than 7% vs. 1.13 for 7% or more).
- SGLT2 inhibitor use (ETR, 1.15 for use vs. 1.15 for nonuse).
- Insulin use (ETR, 1.14 for use vs. 1.17 for nonuse).
Semaglutide also improved pain-free walk distance across all subgroups. The safety profile of semaglutide remained consistent across all subgroups, according to the study results. The findings were published in Diabetes Care.
Subodh Verma, a researcher involved in the study, presented the findings at the American Diabetes Association’s Scientific Sessions. He suggested that the benefits of semaglutide on peripheral arterial disease are not driven by weight loss, as the study population experienced only a small weight loss of about 4 kg. Verma believes this could mark a transformative change in managing peripheral arterial disease, offering a new approach after 25 years for a debilitating condition.
“We don’t beleive that weight is driving this benefit; there was a very small 4 kg weight loss in this population… We think this marks a transformative change in the management of peripheral arterial disease, and it moves the field forward, after 25 years, for a problem that is debilitating for patients,” Verma said.
What’s next
the study’s findings suggest that semaglutide could become a valuable tool in managing peripheral arterial disease in patients with diabetes, addressing a critical need for new treatment options. Further research may explore the specific mechanisms through which semaglutide, a primary_keyword, improves PAD symptoms, potentially leading to even more targeted therapies.